Caribou Biosciences annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Caribou Biosciences Free Cash Flow (FCF) History (CRBU)
Caribou Biosciences reported −$112.4M in free cash flow for fiscal 2025, an increase of $30.7M from the previous fiscal year, with a free cash flow margin of −1006.82%.
View full Caribou Biosciences company overviewCaribou Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$112.4M | $30.7M | — | −1006.82% |
| 2024 | 2024-12-31 | −$143.1M | −$38.2M | — | −1431.66% |
| 2023 | 2023-12-31 | −$104.9M | −$7.5M | — | −304.27% |
| 2022 | 2022-12-31 | −$97.4M | −$62.8M | — | −703.34% |
| 2021 | 2021-12-31 | −$34.6M | −$1.1M | — | −360.91% |
| 2020 | 2020-12-31 | −$33.5M | −$642,000 | — | −271.27% |
| 2019 | 2019-12-31 | −$32.9M | — | — | −568.24% |
Caribou Biosciences quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$22.8M | $5.9M | — | −1520.21% |
| Q1 2026 | 2026-03-31 | −$27.1M | $10.7M | — | −1128.74% |
| Q4 2025 | 2025-12-31 | −$21.0M | $14.9M | — | −533.87% |
| Q3 2025 | 2025-09-30 | −$25.3M | $8.0M | — | −1151.05% |
| Q2 2025 | 2025-06-30 | −$28.7M | $6.4M | — | −1075.22% |
| Q1 2025 | 2025-03-31 | −$37.8M | $884,000 | — | −1605.06% |
| Q4 2024 | 2024-12-31 | −$36.0M | −$12.3M | — | −1732.69% |
| Q3 2024 | 2024-09-30 | −$33.3M | $206,000 | — | −1646.94% |
| Q2 2024 | 2024-06-30 | −$35.1M | −$17.4M | — | −1013.48% |
| Q1 2024 | 2024-03-31 | −$38.7M | −$8.7M | — | −1591.23% |
| Q4 2023 | 2023-12-31 | −$23.7M | $3.1M | — | −664.87% |
| Q3 2023 | 2023-09-30 | −$33.5M | −$9.8M | — | −141.75% |
| Q2 2023 | 2023-06-30 | −$17.7M | $6.8M | — | −472.38% |
| Q1 2023 | 2023-03-31 | −$30.0M | −$7.6M | — | −855.80% |
| Q4 2022 | 2022-12-31 | −$26.8M | −$4.7M | — | −725.92% |
| Q3 2022 | 2022-09-30 | −$23.7M | −$7.8M | — | −718.44% |
| Q2 2022 | 2022-06-30 | −$24.5M | −$7.5M | — | −584.28% |
| Q1 2022 | 2022-03-31 | −$22.4M | −$42.7M | — | −840.69% |
| Q4 2021 | 2021-12-31 | −$22.1M | −$13.4M | — | −862.60% |
| Q3 2021 | 2021-09-30 | −$15.9M | — | — | −399.72% |
| Q2 2021 | 2021-06-30 | −$17.0M | — | — | −1149.05% |
| Q1 2021 | 2021-03-31 | $20.3M | — | — | +1279.38% |
| Q3 2020 | 2020-09-30 | −$8.7M | — | — | −726.63% |
Caribou Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$33.5M to −$112.4M, a net decrease of $78.8M. Caribou Biosciences's latest reported quarter, Q2 2026, generated −$22.8M in free cash flow, an increase of $5.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Caribou Biosciences filings at SEC.gov ↗